Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 12 | 2019 | 212 | 2.540 |
Why?
|
| Prostatectomy | 14 | 2016 | 490 | 2.340 |
Why?
|
| Urethra | 7 | 2020 | 108 | 2.050 |
Why?
|
| Postoperative Complications | 20 | 2017 | 2680 | 1.930 |
Why?
|
| Urinary Sphincter, Artificial | 8 | 2019 | 14 | 1.800 |
Why?
|
| Prostatic Hyperplasia | 11 | 2016 | 104 | 1.790 |
Why?
|
| Penis | 5 | 2015 | 65 | 1.550 |
Why?
|
| Reoperation | 7 | 2017 | 727 | 1.360 |
Why?
|
| Botulinum Toxins, Type A | 6 | 2017 | 56 | 1.290 |
Why?
|
| Urinary Bladder | 10 | 2020 | 261 | 1.150 |
Why?
|
| Urethral Diseases | 3 | 2015 | 15 | 1.150 |
Why?
|
| Risk Assessment | 6 | 2016 | 2580 | 1.130 |
Why?
|
| Neuromuscular Agents | 5 | 2017 | 27 | 1.120 |
Why?
|
| Patient Readmission | 4 | 2017 | 425 | 1.110 |
Why?
|
| Urologic Diseases | 6 | 2016 | 38 | 1.070 |
Why?
|
| Ureter | 4 | 2016 | 80 | 1.020 |
Why?
|
| Cystectomy | 8 | 2016 | 124 | 1.000 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2017 | 98 | 0.990 |
Why?
|
| Suburethral Slings | 5 | 2016 | 87 | 0.960 |
Why?
|
| Penile Prosthesis | 4 | 2017 | 25 | 0.950 |
Why?
|
| Penile Diseases | 2 | 2015 | 8 | 0.900 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 194 | 0.860 |
Why?
|
| Urinary Diversion | 5 | 2016 | 41 | 0.830 |
Why?
|
| Urinary Retention | 4 | 2014 | 43 | 0.690 |
Why?
|
| Laparoscopy | 8 | 2016 | 791 | 0.690 |
Why?
|
| Robotic Surgical Procedures | 3 | 2016 | 411 | 0.670 |
Why?
|
| Urologic Surgical Procedures | 9 | 2017 | 154 | 0.640 |
Why?
|
| Urinary Incontinence | 6 | 2014 | 225 | 0.630 |
Why?
|
| Abdominal Cavity | 1 | 2020 | 17 | 0.620 |
Why?
|
| Urethral Stricture | 2 | 2015 | 17 | 0.620 |
Why?
|
| Replantation | 2 | 2016 | 35 | 0.590 |
Why?
|
| Male | 53 | 2020 | 46996 | 0.550 |
Why?
|
| Humans | 78 | 2020 | 97894 | 0.540 |
Why?
|
| Incontinence Pads | 2 | 2016 | 4 | 0.530 |
Why?
|
| Pubic Bone | 1 | 2017 | 9 | 0.510 |
Why?
|
| Suture Anchors | 1 | 2017 | 7 | 0.510 |
Why?
|
| Urination | 3 | 2016 | 39 | 0.510 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 309 | 0.490 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 64 | 0.490 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 197 | 0.490 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 134 | 0.480 |
Why?
|
| Ureteral Diseases | 1 | 2016 | 11 | 0.480 |
Why?
|
| Surgical Wound | 1 | 2016 | 7 | 0.480 |
Why?
|
| Surgical Flaps | 3 | 2014 | 252 | 0.480 |
Why?
|
| Free Tissue Flaps | 1 | 2017 | 55 | 0.470 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 5 | 0.440 |
Why?
|
| Middle Aged | 36 | 2020 | 29353 | 0.430 |
Why?
|
| Hysterectomy | 1 | 2016 | 174 | 0.430 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 71 | 0.430 |
Why?
|
| Urinary Bladder Neck Obstruction | 5 | 2015 | 26 | 0.420 |
Why?
|
| Follow-Up Studies | 19 | 2016 | 4023 | 0.410 |
Why?
|
| Aged | 33 | 2020 | 21702 | 0.400 |
Why?
|
| Urinary Bladder Diseases | 4 | 2008 | 40 | 0.370 |
Why?
|
| Urinary Tract Infections | 4 | 2017 | 88 | 0.360 |
Why?
|
| Urodynamics | 7 | 2020 | 130 | 0.350 |
Why?
|
| Quality Improvement | 1 | 2016 | 520 | 0.350 |
Why?
|
| Female | 32 | 2020 | 51464 | 0.340 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2016 | 401 | 0.330 |
Why?
|
| Aged, 80 and over | 16 | 2017 | 7386 | 0.320 |
Why?
|
| Rectus Abdominis | 2 | 2008 | 41 | 0.310 |
Why?
|
| Treatment Outcome | 16 | 2016 | 9682 | 0.310 |
Why?
|
| Risk Factors | 8 | 2016 | 6224 | 0.310 |
Why?
|
| Uterine Prolapse | 2 | 2008 | 82 | 0.300 |
Why?
|
| Surgical Mesh | 2 | 2008 | 126 | 0.300 |
Why?
|
| Cystoscopy | 4 | 2015 | 37 | 0.290 |
Why?
|
| Transsexualism | 1 | 2009 | 24 | 0.290 |
Why?
|
| Penile Implantation | 1 | 2009 | 14 | 0.290 |
Why?
|
| Prostatism | 1 | 2008 | 5 | 0.280 |
Why?
|
| Botulinum Toxins | 1 | 2008 | 16 | 0.280 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2008 | 18 | 0.270 |
Why?
|
| Vesicovaginal Fistula | 1 | 2008 | 12 | 0.270 |
Why?
|
| Urination Disorders | 1 | 2008 | 52 | 0.270 |
Why?
|
| Databases, Factual | 4 | 2020 | 1094 | 0.270 |
Why?
|
| Adult | 22 | 2020 | 29453 | 0.260 |
Why?
|
| Prostatic Neoplasms | 6 | 2000 | 1836 | 0.260 |
Why?
|
| Sacrum | 2 | 2017 | 82 | 0.250 |
Why?
|
| Diagnostic Techniques, Urological | 2 | 2017 | 14 | 0.250 |
Why?
|
| United States | 8 | 2017 | 8184 | 0.240 |
Why?
|
| Iatrogenic Disease | 2 | 2016 | 70 | 0.240 |
Why?
|
| Cysts | 1 | 2007 | 100 | 0.240 |
Why?
|
| Time Factors | 8 | 2016 | 5555 | 0.230 |
Why?
|
| Quality of Life | 5 | 2008 | 1891 | 0.230 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2015 | 14 | 0.230 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 184 | 0.230 |
Why?
|
| Fournier Gangrene | 1 | 2005 | 2 | 0.230 |
Why?
|
| Tissue Expansion | 1 | 2005 | 19 | 0.220 |
Why?
|
| Scrotum | 1 | 2005 | 15 | 0.220 |
Why?
|
| Morbidity | 2 | 2016 | 162 | 0.220 |
Why?
|
| Fibula | 1 | 2005 | 32 | 0.220 |
Why?
|
| Prospective Studies | 8 | 2016 | 4798 | 0.220 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2005 | 19 | 0.220 |
Why?
|
| Retrospective Studies | 14 | 2020 | 10947 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 81 | 0.210 |
Why?
|
| Pancreas Transplantation | 1 | 2005 | 120 | 0.210 |
Why?
|
| Device Removal | 2 | 2017 | 170 | 0.200 |
Why?
|
| Administration, Intravesical | 3 | 2008 | 40 | 0.190 |
Why?
|
| Preoperative Care | 3 | 2000 | 418 | 0.190 |
Why?
|
| Hypospadias | 1 | 2002 | 6 | 0.190 |
Why?
|
| Amputation, Traumatic | 1 | 2002 | 9 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 3 | 2000 | 354 | 0.180 |
Why?
|
| Nephrectomy | 2 | 2015 | 290 | 0.180 |
Why?
|
| Urology | 2 | 2001 | 144 | 0.180 |
Why?
|
| Anastomosis, Surgical | 3 | 2016 | 289 | 0.170 |
Why?
|
| Fascia | 1 | 2001 | 32 | 0.170 |
Why?
|
| Incidence | 2 | 2016 | 1776 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2001 | 658 | 0.160 |
Why?
|
| Biofeedback, Psychology | 1 | 2000 | 13 | 0.160 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2000 | 10 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 87 | 0.160 |
Why?
|
| Exercise Therapy | 1 | 2000 | 96 | 0.150 |
Why?
|
| Ureteral Obstruction | 2 | 2002 | 62 | 0.150 |
Why?
|
| Pressure | 2 | 2019 | 173 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 214 | 0.140 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 89 | 0.140 |
Why?
|
| Collagen | 1 | 2000 | 313 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2020 | 176 | 0.140 |
Why?
|
| Phytotherapy | 1 | 1999 | 139 | 0.140 |
Why?
|
| Urinary Catheterization | 4 | 2014 | 40 | 0.130 |
Why?
|
| Cryosurgery | 2 | 1995 | 76 | 0.130 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1997 | 5 | 0.130 |
Why?
|
| Platinum Compounds | 1 | 1997 | 29 | 0.130 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 31 | 0.130 |
Why?
|
| Seminoma | 1 | 1997 | 15 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 2017 | 73 | 0.130 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2008 | 39 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 55 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 14 | 0.120 |
Why?
|
| Length of Stay | 3 | 2016 | 869 | 0.120 |
Why?
|
| Creatinine | 1 | 1997 | 312 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2017 | 236 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 126 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2017 | 183 | 0.120 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 210 | 0.120 |
Why?
|
| Orchiectomy | 1 | 1996 | 64 | 0.110 |
Why?
|
| Pelvis | 1 | 2016 | 106 | 0.110 |
Why?
|
| Abdomen | 1 | 2016 | 120 | 0.110 |
Why?
|
| Anilides | 1 | 1996 | 50 | 0.110 |
Why?
|
| Organ Size | 1 | 2016 | 370 | 0.110 |
Why?
|
| Operative Time | 1 | 2016 | 175 | 0.110 |
Why?
|
| Rupture | 1 | 2015 | 59 | 0.110 |
Why?
|
| Rhabdomyolysis | 1 | 2015 | 28 | 0.110 |
Why?
|
| Steroids | 1 | 2016 | 168 | 0.110 |
Why?
|
| Recurrence | 2 | 2016 | 1254 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 158 | 0.110 |
Why?
|
| Survival Rate | 3 | 2015 | 2040 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2016 | 325 | 0.110 |
Why?
|
| Reference Values | 1 | 2016 | 608 | 0.110 |
Why?
|
| Age Factors | 3 | 2016 | 1960 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 424 | 0.110 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 157 | 0.110 |
Why?
|
| Illinois | 1 | 2016 | 522 | 0.110 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2013 | 29 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2013 | 3202 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 355 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2016 | 297 | 0.100 |
Why?
|
| Urinary Fistula | 1 | 2013 | 7 | 0.100 |
Why?
|
| Ileum | 1 | 2014 | 172 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 304 | 0.100 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 939 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2015 | 518 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2002 | 30 | 0.090 |
Why?
|
| Delirium | 1 | 2012 | 79 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 674 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 872 | 0.090 |
Why?
|
| Sepsis | 1 | 2016 | 401 | 0.090 |
Why?
|
| Urinary Tract | 2 | 2005 | 34 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2783 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 467 | 0.080 |
Why?
|
| Kidney | 1 | 1995 | 1121 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 863 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2000 | 35 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2012 | 968 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1995 | 1536 | 0.070 |
Why?
|
| Hypertension | 1 | 1994 | 778 | 0.070 |
Why?
|
| Stents | 2 | 2002 | 433 | 0.070 |
Why?
|
| Substance P | 1 | 2008 | 62 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2007 | 5 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 23 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 2080 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2008 | 1255 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2008 | 308 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2016 | 1120 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2007 | 229 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2007 | 156 | 0.060 |
Why?
|
| Valsalva Maneuver | 1 | 2006 | 7 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2003 | 2008 | 0.060 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2005 | 4 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Prostate | 2 | 2003 | 434 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 1997 | 238 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 511 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2373 | 0.050 |
Why?
|
| Duodenum | 1 | 2005 | 112 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2005 | 239 | 0.050 |
Why?
|
| Internet | 3 | 2001 | 358 | 0.050 |
Why?
|
| Lithotripsy | 2 | 2000 | 42 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 159 | 0.050 |
Why?
|
| Rats | 3 | 2008 | 4071 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2000 | 359 | 0.050 |
Why?
|
| Urinary Bladder Calculi | 1 | 2002 | 2 | 0.050 |
Why?
|
| Finasteride | 1 | 2002 | 8 | 0.050 |
Why?
|
| International Cooperation | 1 | 2003 | 132 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 425 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 77 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1995 | 0.040 |
Why?
|
| Elasticity | 1 | 2001 | 98 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1009 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2001 | 88 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2000 | 3021 | 0.040 |
Why?
|
| Observer Variation | 1 | 2003 | 579 | 0.040 |
Why?
|
| Cadaver | 1 | 2001 | 202 | 0.040 |
Why?
|
| Postal Service | 1 | 2001 | 24 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2003 | 224 | 0.040 |
Why?
|
| Professional Practice | 1 | 2001 | 43 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2008 | 844 | 0.040 |
Why?
|
| Ureteral Calculi | 1 | 2000 | 9 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 395 | 0.040 |
Why?
|
| Cefazolin | 1 | 2000 | 8 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2000 | 88 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 24 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 226 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 25 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2001 | 282 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 254 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2001 | 351 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 87 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 192 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 93 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 1997 | 23 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2000 | 357 | 0.030 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 9 | 0.030 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 29 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 4112 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 252 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1567 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 1944 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 1996 | 14 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 674 | 0.030 |
Why?
|
| Contracture | 1 | 2015 | 18 | 0.030 |
Why?
|
| Nitriles | 1 | 1996 | 171 | 0.030 |
Why?
|
| Chicago | 1 | 1999 | 1513 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 67 | 0.030 |
Why?
|
| Logistic Models | 1 | 1997 | 1273 | 0.020 |
Why?
|
| Intestines | 1 | 2016 | 441 | 0.020 |
Why?
|
| Microsurgery | 1 | 2014 | 120 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 26 | 0.020 |
Why?
|
| Endoscopy | 1 | 2016 | 385 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 221 | 0.020 |
Why?
|
| Groin | 1 | 2012 | 11 | 0.020 |
Why?
|
| Animals | 4 | 2008 | 28910 | 0.020 |
Why?
|
| Biopsy | 1 | 1994 | 1224 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 724 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 902 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Urothelium | 1 | 2008 | 67 | 0.020 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2005 | 1 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 1750 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 945 | 0.010 |
Why?
|
| Contraindications | 1 | 2000 | 66 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2000 | 45 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 577 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 762 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 212 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 857 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 375 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 985 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 93 | 0.010 |
Why?
|
| Robotics | 1 | 2000 | 271 | 0.010 |
Why?
|
| Child | 2 | 2000 | 7680 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 523 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1997 | 119 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 140 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1781 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 299 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1998 | 1527 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1996 | 520 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1193 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 3329 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2000 | 4000 | 0.010 |
Why?
|
| Hospitalization | 1 | 1997 | 982 | 0.010 |
Why?
|
| Adolescent | 1 | 1997 | 10078 | 0.000 |
Why?
|